

CURRICULUM VITAE

NAME: JACQUELINE MARION KATZ

PLACE OF BIRTH: Melbourne, Australia

CITIZENSHIP: Dual Australian and U.S. citizenship

OFFICE ADDRESS: Chief, Immunology and Pathogenesis Branch
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, Georgia 30333
Telephone: (404) 639-4966

EMAIL ADDRESS: JKatz@cdc.gov

HOME ADDRESS: 447 Hardendorf Ave. N.E.
Atlanta, Georgia 30307
Telephone: (404) 371-8655

ACADEMIC DEGREES:

B.S. 1980 University of Melbourne, Australia (Microbiology, Biochemistry)
Ph.D. 1986 University of Melbourne, Australia (Microbiology)

PROFESSIONAL APPOINTMENTS:

1985-1988 Postdoctoral Fellow, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee

1988-1990 Research Associate, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee

1990 - 1992 Assistant Member, Department of Virology and Molecular Biology,
St. Jude Children's Research Hospital, Memphis Tennessee and
Assistant Professor, Department of Pathology, College of Medicine, The University of Tennessee, Memphis, Tennessee;
Affiliate Appointment (1992)

1992 - Present	Chief, Immunology and Pathogenesis Branch, Influenza Division; Team Leader, Immunology and Viral Pathogenesis Unit, Influenza Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
1993- Present	Adjunct appointments in Departments of Microbiology and Immunology and Pathology, and Graduate Faculty in the Division of Biological and Biomedical Sciences, Immunology and Molecular Pathogenesis Program, Emory University, Atlanta, Georgia.
2007- Present	Associate Editor, International Society for Influenza and Other Respiratory Virus Diseases

RESEARCH INTERESTS:

Development of improved influenza vaccines
 Cell mediated immune responses to respiratory viruses
 Mucosal immunology
 Viral pathogenesis

HONORS AND AWARDS:

1978	Exhibition in Microbiology, University of Melbourne
1978	Australian Society for Microbiology Prize
1980-83	Commonwealth Postgraduate Research Award
1998	NCID Honor Award for H5N1 Outbreak Investigation
1999	James H. Nakano Citation for outstanding scientific paper published in 1998
2000	James H. Nakano Citation for outstanding scientific paper published in 1999
2002	James H. Nakano Citation for outstanding scientific paper published in 2001
2005	NCID Honor Award for Public Health Epidemiology and Laboratory Research for 2004 Avian Influenza Response Team
2005	CDC-ATSDR Honor Award for Public Health Epidemiology and Laboratory Research for 2004 Avian Influenza Response Team
2006	James H. Nakano Citation for outstanding scientific paper published in 2005
2006	Charles C. Shepard Science Award for excellence in laboratory methods publication for 2005

2006 Department of Health and Human Services group award for 2005
Pandemic Influenza Planning and Preparedness Team

PROFESSIONAL SOCIETY MEMBERSHIPS:

American Society for Virology
American Society for Microbiology
International Society for Influenza and Other Respiratory Virus Diseases

COMMITTEES AND MEMBERSHIPS:

St Jude Children's Research Hospital Institutional Animal Care and Use Committee,
1990-1992
CDC Institutional Animal Care and Use Committee, 1996-2006
Editorial review board for Virus Research, 2001-present
Influenza virus representative on the American Society for Virology American Type
Culture Collection advisory committee, 2001-present
Member, Influenza agent summary statement committee for 5th edition of Biosafety in
Microbiological and Biomedical Laboratories, 2004-2005
Chair, Scientific Program Committee for Options for the Control of Influenza VI,
Toronto, Canada, 2007
Ph.D. thesis committee member for graduate students in the Immunology and Molecular
Pathogenesis and Microbiology and Molecular Genetics Programs, Emory University (9
students to date)
Treasurer, International Society for Influenza and Other Respiratory Virus Diseases,
2007
Center Grant Scientific Advisory Board, Blood Center of Wisconsin, Blood Research
Institute, National Institutes of Health, 2008

AD HOC JOURNAL REVIEWER:

Archives of Virology
Clinical and Diagnostic Lab Immunology
Emerging Infectious Diseases
Journal of Clinical Microbiology
Journal of Immunology
Journal of Immunological Methods
Journal of Infectious Diseases
Journal of Medical Virology
Journal of Virological Methods
Journal of Virology
International Society for Influenza and Other Respiratory Virus Diseases
The Lancet
Nature

Nature Medicine
Vaccine
Virology
Virus Research

AD HOC GRANTS REVIEWER:

National Institutes of Health, NIAID, Experimental Virology
Wellcome Trust
U.S. Department of Agriculture, Animal Health

INVITED PRESENTATIONS AND MEETING ACTIVITIES:

1. Host-cell selection of influenza virus variants. NIH/NIAID Workshop on Live Attenuated Influenza Vaccines, Bethesda, MD, October, 1987.
2. Differential immunogenicity and efficacy of host-cell selected influenza variant vaccines in ferrets. NIH/NIAID Workshop on Live Attenuated Influenza Vaccines, Arlington, VA, October, 1989.
3. Host cell selection of influenza virus variants. University of Melbourne, Melbourne, Australia, December 1990.
4. Host cell-mediated selection of influenza viruses: consequences for vaccines. Veterinary Research Institute, Attwood, Victoria, Australia, December 1990.
5. Host cell-mediated variation in influenza A H3N2 viruses. WHO-NIH meeting on Host Cell Selection of Influenza Virus Variants, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom, November 1991.
6. Improved vaccines against influenza. Department of Microbiology and Immunology, Emory University, Atlanta Georgia, February, 1993.
7. Immunity to influenza viruses. Department of Infectious Diseases, Emory University, Atlanta Georgia, April 1993.
8. Enterotoxin (LT) from *Escherichia coli* as an adjuvant for oral immunization with influenza vaccine. IBC Conference Series Strategies for Mucosal Vaccination, Bethesda MD, October 1993.
9. Efficacy of LT adjuvant for oral immunization with influenza vaccine. Workshop on LT Adjuvant. Navy Medical Research Institute, Bethesda, MD, October, 1993.

10. Protective immunity to conserved influenza A virus proteins. Pierre Fabre Medicament Centre d'Immunologie et de Biotechnologie. Saint-Julien-en-Genevois, France, October, 1994.
11. Heat labile enterotoxin (LT) from *Escherichia coli* as an adjuvant for mucosal influenza vaccination. Institute for Advanced Studies in Immunology and Aging meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in Adults. November, 1995.
12. Molecular evolution of human influenza A viruses. American Association for the Advancement of Science Annual Meeting, Atlanta Georgia, April 1996.
13. Participant, workshop on population biology, evolution and immunology of vaccination. Emory University, April, 1996.
14. Heat labile enterotoxin (LT) from *Escherichia coli* as an adjuvant for oral influenza vaccination. Options for the Control of Influenza III, Cairns, Australia, May 1996.
15. Chair for Viral Immunology Session, American Society for Virology Annual Meeting, London, Ontario, July 1996.
16. Stimulation of T cell immune responses by oral influenza vaccination with enterotoxin LT. Fourth Annual Working Group Meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in Adults. Washington, D.C. October, 1996.
17. LT as a mucosal adjuvant for oral influenza vaccine in mice. SmithKline Beecham, Rixensart, Belgium, November, 1996.
18. Control and prevention of influenza viruses. Augusta State University, Augusta Georgia, March 1997.
19. Invited presentation at Advisory Committee for Immunization Practices Working Group Meeting on Live Attenuated Influenza Vaccines, May 1997.
20. Influenza as an emerging infectious disease. Louisiana State University, Shreveport, LA, September 1997.
21. Emergence of avian influenza viruses in humans, University of East Michigan, Kalamazoo, Michigan, October 1997.
22. Serological studies on H5N1 viruses in humans. H5N1 Roundtable Workshop. Washington, DC, March 1998.
23. Chair for Viral Immunology Session, American Society for Virology Annual Meeting, Vancouver, British Columbia, July 1998.

24. Update on serological responses in humans to H5N1 infection and vaccination. NIAID Meeting to Discuss H5/H7 Avian Strains for Candidate Vaccines. Rockville, MD, September 1998.
25. Serological responses in humans to H5N1 infection and vaccination. FDA Vaccine and Related Biological Products Advisory Committee Meeting, January 1999.
26. Alternatives for new influenza vaccines against an emerging pandemic virus. VI Congreso Nacional de Virologia, Majadahonda, Spain, October 1999.
27. Vaccines against influenza A (H9N2) viruses. Options for the Control of Influenza IV, Hersonissos, Crete, Greece, September 2000.
28. Chair for Determinants of Pathogenicity Session, Options for the Control of Influenza, IV, Crete, Greece, September 2000.
29. Pathogenicity of and immunity to avian influenza A viruses in mammalian species. Emory Vaccine Research Center, Emory University, Atlanta Georgia, November 2000.
30. Invited presentation at Advisory Committee for Immunization Practices Working Group Meeting on Live Attenuated Influenza Vaccines, Atlanta Georgia, May 2001.
31. Evaluation of novel influenza A viruses in humans and the 1997 Hong Kong experience. Third International Conference on Emerging Zoonoses, Noordwijkerhout, Holland, October 2001
32. Pathogenesis of avian influenza A H5N1 viruses in mammals. Southeastern Branch of the American Society of Microbiology Annual Meeting, November, 2001.
33. Pathogenesis of avian influenza viruses in mammals. University of Melbourne, Melbourne Australia, December, 2001.
34. Heterosubtypic immunity and the quest for a pandemic influenza vaccine. La Jolla Institute for Allergy and Immunology. San Diego, California, March, 2002.
35. Impact of avian influenza viruses on public health. Fifth International Symposium on Avian Influenza, Athens, Georgia, April 2002.
36. Current methods for assessing T cell responses to influenza. Laboratory Correlates of Immunity to Influenza- A Reassessment. University of Bergen, Bergen Norway, May 2002.

37. Assays for neutralizing antibody. Scientific workshop on neutralizing antibody assays for influenza virus. Dresden, Germany, March 2003.
38. Pandemic influenza: current perspectives. 103rd general meeting American Society for Microbiology, Washington, D.C., May 2003
39. Co-chair, Immunology Workshop, Options for the Control of Influenza V, Okinawa, Japan, October 2003.
40. Expert reviewer for Lung Program Project Grant, Trudeau Institute, Saranac Lake, NY, October, 2003
41. Vaccines for avian influenza viruses with pandemic potential. Hong Kong International Conference on Infectious Diseases, Hong Kong, Hong Kong SAR, January-February, 2004.
42. The immune response to influenza. WHO Animal Influenza Network Training Course, Hong Kong, Hong Kong SAR, March, 2004.
43. Development of Pandemic Vaccines. International Workshop on Development of Vaccines for SARS and New Human Influenza Vaccines, Beijing, PRC, March 2004.
44. The “Flu Brew”: influenza vaccine strain selection. General Meeting of the American Society for Microbiology, New Orleans, LA, May, 2004.
45. Translational challenges: from basic immunology to public health. International symposium on innate and adaptive immunity after transcutaneous or mucosal vaccination, Veyrier-du-Lac, France, June 2004.
46. Invited participant, Safety Considerations in Recombinant DNA Research with Pathogenic Viruses; NIH Recombinant DNA Advisory Committee Meeting, Bethesda, Maryland, September, 2004.
47. Moderator, Symposium on Influenza, 42nd Annual Meeting of The Infectious Diseases Society of America, Boston, Massachusetts, October 2004.
48. Influenza virus pathogenesis in mammalian species, 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, Massachusetts, October 2004.
49. Vaccines against pandemic influenza. Center for Immunotherapy of Cancer and Infectious Disease, University of Connecticut Health Center, Farmington, Connecticut, October 2004.

50. Vaccines for epidemic and pandemic influenza. Department of Biology, Georgia State University, Atlanta, Georgia, November 2004.
51. Avian influenza viruses with pandemic potential (Keynote speaker), Tennessee Academy of Science Annual Meeting, Columbus, Tennessee, November, 2004.
52. Pandemic influenza vaccines, New York Academy of Science Meeting, New York, New York, December 2004.
53. World Health Organization Consultation on Immunological Assays to Evaluate Efficacy of Influenza Vaccines, Geneva, Switzerland, January, 2005.
54. Invited Participant, Institute of Medicine John LaMontagne Memorial Symposium on Pandemic Influenza Research, Washington D.C., April, 2005.
55. Keynote presentation at the Federation of Animal Sciences Society Meeting on The Public Health Impact of Avian Influenza, Atlanta, GA, April 2005.
56. Influenza vaccines: taking aim at a moving target, The Trudeau Institute, Saranac Lake, New York, May 2005.
57. Biological containment for work with non-contemporary strains of influenza, NIH Recombinant DNA Advisory Committee Meeting, Washington D.C., June 2005.
58. Avian H5N1 influenza viruses. Southern Research Institute, Birmingham, Alabama, August, 2005.
59. The pandemic potential of avian influenza. 3rd Global Experts Meeting on Respiratory Viruses. Budapest, Hungary, September, 2005.
60. Influenza vaccines: epidemiology and scientific gaps. The Doctor Goes Back to the Lab: Bringing basic science to the bedside. Atlanta GA, October 2005.
61. Scientific review board member, Blood Center of Wisconsin U19 grant on Human Immunology, November 2005.
62. Laboratory Evaluation and Standardization of Antibody Responses. Regulatory Preparedness Workshop on Human Vaccines for Pandemic Influenza. Ottawa, Canada, March, 2006.
63. Biology of influenza and pandemic potential of avian influenza viruses. Association of Medical Microbiology and Infectious Diseases Canada and Canadian Association for Clinical Microbiology and Infectious Diseases Annual Conference, Victoria, British Columbia, March, 2006.

64. Avian Influenza Virus Pathogenesis in Animal Models. Advances in influenza research: from birds to bench to bedside. Steamboat Springs, Colorado, March, 2006.
65. The pandemic potential of avian influenza viruses. 2006 Fellows Symposium, Research Triangle Institute, Chapel Hill, NC April 2006
66. Immunity to avian influenza viruses: implications for pandemic preparedness. AAI committee on public affairs: why immunology research may save the world symposium. Annual meeting of the American Association of Immunologists, Boston, MA, May 2006.
67. The pandemic potential of avian influenza viruses. The University of Rochester, Rochester NY, June 2006.
68. Pathogenesis and transmissibility of avian H5N1 viruses in mammals. Biochemistry and Molecular Biology Department, University of Oklahoma Seminar, September 2006.
69. H1 test using horse cells. World Health Organization on Standardization of Microneutralization of Assays for Influenza Viruses, Copenhagen, Denmark October 2006
70. Invited seminars at Case Western Reserve University (departmental seminar and graduate student course) on Virus Host interactions, Cleveland, Ohio November 2006
71. Mouse as an animal model for the evaluation of novel antivirals. Development and Use of Antivirals for Pandemic Influenza, Department of Health and Human Services, National Institute of Health. Bethesda, MD November 2006
72. Addressing the pandemic threat of avian influenza. US-Japan Cooperative Medical Science Program 11th International Conference on Emerging Infectious Diseases in the Pacific Rim, Singapore November 2006
73. Pandemic potential of avian influenza viruses. International Vaccine Institute, Seoul, Korea November 2006
74. Pathogenesis and transmissibility of avian influenza viruses. Respiratory Viruses of Animals Causing Disease in Humans, Keystone Symposium, Singapore, December 2006
75. Taking aim at a moving target. Department of Comparative Pathobiology, Perdue University, NIH Adenoviral Vector-Based Pandemic Influenza Vaccine. West Lafayette, IN January 2007
76. Animal models of avian influenza virus pathogenesis and their use in pandemic vaccine evaluation. The IX National Congress of Virology at Zaragoza University Centre for Prionic Diseases Research on behalf of the Spanish Society of Virology, Zaragoza Spain, April 2007

77. Chair, Scientific Program Committee; Chair of Plenary Session, Molecular Basis of Virulence and Transmissibility, Options for the Control of Influenza VI conference, Toronto, Canada, June 2007
78. Influenza A virus pathogenesis and transmissibility in mammals. Immunobiology of Influenza Virus Infection: Approaches for an Emerging Zoonotic Disease, University of Georgia, Athens, GA, July 2007
79. Keynote address. 4th Orthomyxovirus Research Conference, The University of Wisconsin, Woods Hole, MA, September 2007
80. Keynote address. Australian Influenza Symposium 2007 at the John Curtin School of Medical Research, Canberra Australia, October 2007
81. Invited guest Melbourne Collaborating Centre for Influenza, Melbourne, Australia, October 2007
82. Serological studies at the animal-human interface. International Symposium on Avian Influenza: Epidemiologic, Basic and Applied Research, New Delhi, India, October 2007
83. NCIRD Presentation Speaker. Novel Prevention and Therapeutic Strategies against Influenza Viruses. December 2007.
84. Immune responses in poultry workers. Immune Correlates of Protection against Influenza A Viruses in Support of Pandemic Vaccine Development, FDA/NIH/WHO, Bethesda, MD, December 2007.
85. Assessment of Pandemic Risk through Pathogenesis and Transmission Animal Models Studies and Serologic Studies. CDC-NIH Influenza Program Coordination Meeting, Bethesda, MD, January 2008.
86. Molecular Pathology of Avian Influenza Infections in Humans. Bangkok International Conference on Avian Influenza 2008: Integration from Knowledge to Control, Bangkok, Thailand, January 2008.
87. US Japan Acute Respiratory Infections Panel Meeting. Bethesda, MD, February 2008.
88. Influenza Division Laboratory Infrastructure. Thailand NIH Study, Atlanta, GA, March, 2008.
89. Highlights from the Bangkok International Conference on Avian Influenza 2008: Integration from Knowledge to Control. The Influenza Division Journal Club, CDC, Atlanta, GA, 2008.